cerca CERCA
Mercoledì 30 Novembre 2022
Aggiornato: 09:13
Temi caldi

Chimica_E_Farmacia Salute_E_Benessere Chimica_E_Farmacia Economia_E_Finanza

comunicato stampa

OncoOne and GenScript ProBio Enter Agreement for the Manufacturing of Monoclonal Antibody Drugs Targeting oxMIF

LEIDEN, Netherlands, Nov. 17, 2021 /PRNewswire/ -- OncoOne, a biotechnology company focused on discovering precision medicines for cancer and other indications and GenScript ProBio, a leading CDMO in biologics and gene cell therapy, today announced that the companies have entered into an agreement for the cell line development, drug substance and drug product manufacturing of therapeutic and diagnostic monoclonal antibodies (mAbs) directed against the promising immuno-oncology target, oxidized ma...

comunicato stampa

Yuyu Pharma Signs Exclusive Distribution Agreement with Novartis Korea for Domestic Distribution Rights in Korea for Lamisil®, Lescol® XL and Tegretol®

SEOUL, South Korea, Aug. 3, 2021 /PRNewswire/ -- Yuyu Pharma, a pharmaceutical company based in Korea, and Novartis Korea announced today that the companies have entered into an agreement in which Yuyu will have exclusive distribution rights for the following prescription medicines in Korea: Lamisil® for the treatment of athlete's foot; Lescol® XL for the treatment of dyslipidemia; and the Tegretol® for the treatment of epilepsy. This agreement will be in effect beginning August 1st, 2021.

WuXi Biologics Completed Three Acquisitions to Enhance its Global Network

SHANGHAI, May 7, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that it has completed the acquisitions of a Bayer manufacturing facility in Wuppertal, Germany, the Pfizer China ("Pfizer") manufacturing facilities in Hangzhou, China as well as CMAB Biopharma Group ("CMAB").

WuXi Vaccines Achieves Weather-Tight Construction Milestone on Main Building of Manufacturing Facility Despite COVID-19

SHANGHAI and DUNDALK, Ireland, March 16, 2021 /PRNewswire/ -- WuXi Vaccines, a world-leading vaccine Contract Development and Manufacturing Organization (CDMO), today announced it achieved the weather-tight construction milestone of its vaccine manufacturing facility currently under construction in Dundalk, Ireland, while the company demonstrated extraordinary resilience despite COVID-19 challenges. The facility is expected to be operational in 2022. The modular lab was already in GMP operations ...

WinHealth and Immedica enter agreement giving Winhealth rights to Ravicti® in China and several other Asia-Pacific countries

STOCKHOLM and HANGZHOU, China, Dec. 31, 2020 /PRNewswire/ -- Hongkong WinHealth Pharma Group CO., Ltd and Immedica Pharma AB, today announce that they have entered an agreement under which WinHealth gains the exclusive commercial rights to Ravicti® (glycerol phenylbutyrate), in a territory covering the Greater China Area, South Korea, Singapore, Vietnam, Indonesia, Malaysia, Philippines and Thailand.

Executive from Yuyu Pharma Receives Presidential Commendation for Gender Equality Employment

SEOUL, South Korea, Sept. 4, 2020 /PRNewswire/ -- Eugene Baik, Head of Production at Yuyu Pharma (CEO Robert Wonsang Yu, KRX 000220), received the Presidential Commendation for contributions in leading the realization of gender equality employment. The award was given at the 2020 Gender Equality Award Ceremony held on the 31st at the Government's Seong Convention Center.

WuXi Vaccines Appoints Mr. Jian Dong as Chief Executive Officer

SHANGHAI and DUNDALK, Ireland, Aug. 6, 2020 /PRNewswire/ -- WuXi Vaccines, a global leading company with world-class vaccine contract development and manufacturing organization (CDMO) capabilities, is pleased to announce the appointment of Mr. Jian Dong as Chief Executive Officer (CEO). WuXi Vaccines is a joint venture established between WuXi Biologics and Shanghai-based Hile Bio-Technology.

CF PharmTech, Inc. Closes a US $50M Series F Financing to Accelerate the Commercialization of its Inhalation Products.

SUZHOU, China, July 2, 2020 /PRNewswire/ -- CF PharmTech, Inc. ("CF PharmTech") announced today that it has raised US $50M in Series F financing following its US $90M Series E financing in January of 2020, in total, successfully completing an equity investment deal of nearly US $140M within six months. The investors participated in the Series F financing include BioTrack Capital, CICC Qichen, CICC Qide, SAIC Hengxu, GP M&A Fund and Watson Investment. Its existing investors including Passion Capit...

ora in
Prima pagina
in Evidenza